newsfilter
← Latest News
GlobeNewswire·

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases,